ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Divestitures (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Business Acquisition [Line Items]
Net Proceeds	$ 223	$ 206		$ 631	$ 791
Divestiture (Gains)/Losses	0	0		0	211
Royalty Income	217	205		623	597
Diabetes business - royalties
Business Acquisition [Line Items]
Net Proceeds	220	205		621	562
Divestiture (Gains)/Losses	0	0		0	0
Royalty Income	217	205		623	595
Mature products and other
Business Acquisition [Line Items]
Net Proceeds	3	1		10	229
Divestiture (Gains)/Losses	0	0		0	211
Royalty Income	$ 0	$ 0		$ 0	$ 2
Mature products and other | Cheplapharm
Business Acquisition [Line Items]
Net Proceeds			$ 221
Divestiture (Gains)/Losses			$ 211